title: Symptomatic management in multiple sclerosis.
abstract: The development of immunomodulatory therapies for multiple sclerosis (MS) has had significant impact in altering the natural history of the disease. Although these agents reduce relapse rate and MRI-associated disease activity, they are only partially effective and do not ameliorate irreversible axonal injury, which produces much of the symptomatic burden of MS. Treatment of MS-associated symptoms remains an essential cornerstone of comprehensive care of patients with MS and, arguably, more favorably enhances quality of life than do the disease-modifying medications. This article reviews strategies of symptom management in patients with MS.
authors: Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
authors: Lawrence M
authors: LM
authors: Samkoff
authors: Andrew D
authors: AD
authors: Goodman
mesh_terms: D003072:Cognition Disorders / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D005221:Fatigue; D020233:Gait Disorders, Neurologic; D006801:Humans; D019964:Mood Disorders; D009103:Multiple Sclerosis / Q000150:complications* / Q000175:diagnosis / Q000628:therapy*; D009128:Muscle Spasticity; D010146:Pain / Q000175:diagnosis; D012735:Sexual Dysfunction, Physiological / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D014202:Tremor; D001750:Urinary Bladder, Neurogenic / Q000175:diagnosis / Q000209:etiology / Q000628:therapy